위장관 진단 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 검사 유형별, 기술별, 용도별, 검사장소별, 지역별＆경쟁(2021-2031년)
Gastrointestinal Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Technology, By Application, By Test Location, By Region & Competition, 2021-2031F
상품코드:1951271
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 위장관 진단 시장은 2025년 55억 8,000만 달러에서 2031년까지 73억 3,000만 달러로 성장하고, CAGR 4.65%를 나타낼 것으로 예측됩니다.
이 분야는 장, 위, 식도를 포함한 소화관 전체의 병태를 확인하기 위해 설계된 전문 분석 키트, 영상 기술, 의료 검사 플랫폼으로 구성되어 있습니다. 시장 성장은 빈번한 임상 검진을 필요로 하는 고령화 인구와 기능 장애 및 소화기 악성 종양의 유병률 증가로 인해 근본적으로 뒷받침되고 있습니다. 이러한 촉진요인은 질병 모니터링 및 조기 발견 능력에 대한 수요의 지속적인 구조적 증가를 나타내며, 일시적인 산업 트렌드와 차별화됩니다.
시장 개요
예측 기간
2027-2031년
시장 규모 : 2025년
55억 8,000만 달러
시장 규모 : 2031년
73억 3,000만 달러
CAGR : 2026-2031년
4.65%
가장 성장이 빠른 부문
내시경 검사
최대 시장
북미
미국암협회에 따르면, 2024년에는 미국에서 약 15만 2,810건의 대장암이 새로 진단될 것으로 예상되며, 높은 질병 부담을 고려할 때 정확한 진단 도구의 필요성이 대두되고 있습니다. 그러나 분자검사 장비나 첨단 내시경 시스템에는 막대한 설비투자가 필요하기 때문에 시장 확대에 큰 장벽이 존재합니다. 이러한 고비용의 장벽은 예산이 제한된 의료 환경에서 접근성을 제한하고, 결과적으로 이러한 첨단 진단 기술의 보급을 방해하고 있습니다.
시장 성장 촉진요인
만성 소화기 질환 및 소화기 암의 유병률 증가는 세계 위장관 진단 시장의 주요 촉진요인으로 작용하고 있습니다. 위암, 대장암, 췌장암 등 악성 종양의 발생률이 증가함에 따라 의료 시스템은 높은 사망률을 낮추기 위해 조기 발견을 우선시할 수밖에 없으며, 이로 인해 첨단 영상 진단법 및 기존 내시경 장비에 대한 지속적인 수요가 발생하고 있습니다. 예를 들어, 미국암협회(American Cancer Society)의 'Cancer Facts &&Figures 2024'에 따르면, 췌장암은 여전히 치사율이 높아 같은 해에만 미국에서만 약 5만 1,750명이 사망할 것으로 예상된다고 보고했습니다. 이러한 수요를 반영하여 올림푸스 주식회사는 2024년 5월 내시경 솔루션 부문이 2024년 3월기에 5,866억 엔의 매출을 달성했다고 보고하여 침습적 진단 도구에 대한 지속적인 의존도를 확인할 수 있었습니다.
한편, 시장에서는 재택 및 현장 진단 솔루션에 대한 수요 증가를 배경으로 큰 변화가 일어나고 있습니다. 보험사 및 환자들은 기존 대장내시경 검사에 비해 순응도와 편의성이 개선된 대변 DNA 검사 등 비침습적 검진 방법을 점점 더 선호하고 있으며, 이로 인해 미수검자까지 진단 범위가 확대되고 있습니다. 이러한 변화는 시장 리더의 재무 실적에 큰 영향을 미치고 있습니다. Exact Sciences는 2024년 2월, 2023 회계연도 전체에서 Cologuard 검사를 중심으로 한 스크리닝 수익이 31% 증가한 18억 7,000만 달러에 달했다고 보고하며 비침습적 대안의 상업적 타당성을 입증했습니다.
시장의 과제
위장관 진단 시장의 성장을 크게 저해하는 요인은 첨단 분자 검사 장비와 내시경 시스템에 필요한 막대한 설비 투자입니다. 의료시설, 특히 비용에 민감한 지역 외래 진료소나 지역 병원은 한정된 예산으로 운영되는 경우가 많아 이러한 플랫폼의 고가의 초기 도입 비용을 감당할 수 없는 경우가 많습니다. 그 결과, 이러한 재정적 장벽으로 인해 구식 장비를 장기간 사용하게 되고, 고처리량 기술 도입이 지연되고, 장비 교체 주기가 최적의 임상 일정을 크게 초과하여 검사 건수 증가가 구조적으로 둔화되고 있습니다.
이러한 경제적 부담은 고가의 진단기기에 대한 투자수익률을 떨어뜨리는 상환 환경의 축소로 인해 더욱 심화되고 있습니다. 예를 들어, 미국소화기학회(ACG)는 확정된 2025년도 메디케어 의사 보수 스케줄에서 지불환산계수가 2.83% 삭감된 것을 지적했습니다. 이러한 상환율의 감소는 소화기병 클리닉의 영업 이익률을 직접적으로 침식하고, 고가의 진단용 자본 장비에 대한 투자 능력을 심각하게 제한합니다. 그 결과, 시장 전체의 성장 궤도를 저해하는 요인이 될 수 있습니다.
시장 동향
내시경 영상 시스템에 인공지능(AI)의 통합은 소화기 병변의 검출 기준을 근본적으로 재정의하고 있습니다. 딥러닝 알고리즘은 현재 컴퓨터 보조 감지 시스템에서 동영상 피드를 실시간으로 분석하여 인간의 관찰로는 놓칠 수 있는 폴립과 병변을 식별함으로써 선종 발견률이라는 중요한 변수를 해결하고 환자의 치료 결과를 개선하고 있습니다. 이러한 자동화 도구의 우수한 임상적 유효성이 시장 출시와 규제 당국의 승인을 촉진하고 있습니다. 예를 들어, 2024년 3월 후지필름 헬스케어 아메리카(Fujifilm Healthcare America)는 새로 승인된 CAD EYE AI 시스템이 표준 고화질 대장내시경 검사에 비해 대장내시경 검사 건당 선종 검출률이 17% 더 높다는 것을 입증했다고 발표했습니다.
동시에 복잡한 재처리 워크플로우를 없애고 교차 오염 위험을 줄이기 위해 시장은 일회용 내시경으로 전환하고 있습니다. 병원에서는 환자 안전과 고가의 재사용 장비 세척에 따른 운영 비용 절감을 위해 고위험 시술에 멸균된 일회용 기기를 사용하는 경향이 증가하고 있습니다. 이러한 전환은 일회용 플랫폼의 급속한 상업적 확장으로 두드러지게 나타나고 있습니다. 2024년 11월, 앰부 A/S는 2023/24 회계연도 내시경 솔루션 부문의 유기적 수익이 19.7% 증가했다고 보고했으며, 이는 일회용 내시경이 표준 임상 진료에 빠르게 통합되고 있음을 반영합니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 위장관 진단 시장 전망
제6장 북미의 위장관 진단 시장 전망
제7장 유럽의 위장관 진단 시장 전망
제8장 아시아태평양의 위장관 진단 시장 전망
제9장 중동 및 아프리카의 위장관 진단 시장 전망
제10장 남미의 위장관 진단 시장 전망
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 위장관 진단 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
제15장 경쟁 구도
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
The Global Gastrointestinal Diagnostics Market is projected to expand from USD 5.58 Billion in 2025 to USD 7.33 Billion by 2031, registering a CAGR of 4.65%. This sector comprises a specialized array of assay kits, imaging technologies, and medical testing platforms engineered to identify pathological conditions across the digestive tract, including the intestines, stomach, and esophagus. The market's growth is fundamentally anchored by an aging global population necessitating frequent clinical screening and the rising prevalence of functional disorders and gastrointestinal malignancies. These drivers represent a durable structural increase in the demand for disease monitoring and early detection capabilities, distinguishing them from temporary industry trends.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 5.58 Billion
Market Size 2031
USD 7.33 Billion
CAGR 2026-2031
4.65%
Fastest Growing Segment
Endoscopy
Largest Market
North America
According to the American Cancer Society, approximately 152,810 new cases of colorectal cancer were anticipated to be diagnosed in the United States in 2024, highlighting the urgent need for accurate diagnostic tools given the high disease burden. However, market expansion faces a significant hurdle due to the substantial capital expenditures required for molecular testing equipment and advanced endoscopic systems. This high cost barrier restricts accessibility in budget-constrained healthcare environments, thereby limiting the broader adoption of these advanced diagnostic technologies.
Market Driver
The escalating prevalence of chronic digestive disorders and gastrointestinal cancers acts as the primary catalyst for the Global Gastrointestinal Diagnostics Market. As the incidence of malignancies like gastric, colorectal, and pancreatic cancers rises, healthcare systems are forced to prioritize early detection to lower high mortality rates, creating sustained demand for advanced imaging modalities and established endoscopic hardware. For example, the American Cancer Society's 'Cancer Facts & Figures 2024' noted that pancreatic cancer remains highly lethal, with an estimated 51,750 deaths expected in the U.S. alone that year. Reflecting this demand, Olympus Corporation reported in May 2024 that its Endoscopic Solutions Division achieved revenue of 586.6 billion JPY for the fiscal year ended March 31, 2024, confirming the continued reliance on invasive diagnostic tools.
Concurrently, the market is undergoing a significant transformation driven by the growing preference for at-home and point-of-care diagnostic solutions. Payers and patients are increasingly favoring non-invasive screening methods, such as stool-based DNA tests, which improve compliance and convenience compared to traditional colonoscopies, thus extending diagnostic reach to under-screened populations. This shift has notably impacted the financial performance of market leaders; Exact Sciences Corp. reported in February 2024 that its screening revenue, largely driven by Cologuard tests, grew by 31 percent to 1.87 billion USD for the full year 2023, demonstrating the commercial viability of non-invasive options.
Market Challenge
A major restraint on the growth of the gastrointestinal diagnostics market is the significant capital expense required for advanced molecular testing equipment and endoscopic systems. Healthcare facilities, particularly outpatient clinics and community hospitals in cost-sensitive areas, often operate with limited budgets that cannot support the high upfront procurement costs of these platforms. Consequently, these financial barriers force the prolonged use of legacy instrumentation and delay the adoption of higher-throughput technologies, leading to a structural deceleration in volume growth as equipment replacement cycles extend well beyond optimal clinical timelines.
This economic strain is further intensified by a contracting reimbursement landscape that reduces the return on investment for expensive diagnostic assets. For instance, the American College of Gastroenterology noted that the finalized 2025 Medicare Physician Fee Schedule included a 2.83 percent reduction in the payment conversion factor. Such cuts in reimbursement rates directly erode the operating margins of gastroenterology practices, severely limiting their financial capacity to invest in high-cost diagnostic capital equipment and thereby hindering the market's overall growth trajectory.
Market Trends
The integration of artificial intelligence into endoscopic imaging systems is fundamentally redefining detection standards for gastrointestinal pathologies. Deep learning algorithms are now utilized in computer-aided detection systems to analyze video feeds in real-time, identifying polyps and lesions that might otherwise be missed by human observation, thereby addressing the critical variable of adenoma detection rates and improving patient outcomes. The superior clinical efficacy of these automated tools is driving market adoption and regulatory clearances; for example, Fujifilm Healthcare Americas Corporation announced in March 2024 that its newly cleared CAD EYE AI system demonstrated a 17 percent higher adenoma per colonoscopy rate compared to standard high-definition colonoscopy.
Simultaneously, the market is shifting toward single-use disposable endoscopes to eliminate complex reprocessing workflows and mitigate cross-contamination risks. Hospitals are increasingly adopting these sterile, one-time-use devices for high-risk procedures to ensure patient safety and reduce the operational overhead associated with cleaning capital-intensive reusable equipment. This transition is evident in the rapid commercial expansion of disposable platforms; Ambu A/S reported in November 2024 that organic revenue for its Endoscopy Solutions division increased by 19.7 percent for the 2023/24 financial year, reflecting the accelerating integration of disposable scopes into standard clinical practice.
Key Market Players
bioMerieux S.A.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories, Inc.
Beckman Coulter, Inc.
DiaSorin S.p.A
Siemens Healthineers AG
QIAGEN N.V.
Meridian Bioscience, Inc.
Hologic, Inc.
Epitope Diagnostics Inc.
Report Scope
In this report, the Global Gastrointestinal Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Gastrointestinal Diagnostics Market, By Test Type
Endoscopy
Blood Test
H. pylori Test
Calprotectin Test
Immunoglobulin A Test
and Others
Gastrointestinal Diagnostics Market, By Technology
ELISA
PCR
Microbiology
and Others
Gastrointestinal Diagnostics Market, By Application
Infection
Inflammatory Bowel Disease
Gastroesophageal Reflux Disease
Cancer
and Others
Gastrointestinal Diagnostics Market, By Test Location
Central laboratories and Point-of-Care
Gastrointestinal Diagnostics Market, By Region
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal Diagnostics Market.
Available Customizations:
Global Gastrointestinal Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Gastrointestinal Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type (Endoscopy, Blood Test, H. pylori Test, Calprotectin Test, Immunoglobulin A Test, and Others)
5.2.2. By Technology (ELISA, PCR, Microbiology, and Others)
5.2.3. By Application (Infection, Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Cancer, and Others)
5.2.4. By Test Location (Central laboratories and Point-of-Care)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Gastrointestinal Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Technology
6.2.3. By Application
6.2.4. By Test Location
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Gastrointestinal Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Application
6.3.1.2.4. By Test Location
6.3.2. Canada Gastrointestinal Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Application
6.3.2.2.4. By Test Location
6.3.3. Mexico Gastrointestinal Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Application
6.3.3.2.4. By Test Location
7. Europe Gastrointestinal Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Technology
7.2.3. By Application
7.2.4. By Test Location
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Gastrointestinal Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Application
7.3.1.2.4. By Test Location
7.3.2. France Gastrointestinal Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Application
7.3.2.2.4. By Test Location
7.3.3. United Kingdom Gastrointestinal Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Application
7.3.3.2.4. By Test Location
7.3.4. Italy Gastrointestinal Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Application
7.3.4.2.4. By Test Location
7.3.5. Spain Gastrointestinal Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Application
7.3.5.2.4. By Test Location
8. Asia Pacific Gastrointestinal Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Technology
8.2.3. By Application
8.2.4. By Test Location
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Gastrointestinal Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Application
8.3.1.2.4. By Test Location
8.3.2. India Gastrointestinal Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Application
8.3.2.2.4. By Test Location
8.3.3. Japan Gastrointestinal Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Application
8.3.3.2.4. By Test Location
8.3.4. South Korea Gastrointestinal Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Application
8.3.4.2.4. By Test Location
8.3.5. Australia Gastrointestinal Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Application
8.3.5.2.4. By Test Location
9. Middle East & Africa Gastrointestinal Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Technology
9.2.3. By Application
9.2.4. By Test Location
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Gastrointestinal Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Application
9.3.1.2.4. By Test Location
9.3.2. UAE Gastrointestinal Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Application
9.3.2.2.4. By Test Location
9.3.3. South Africa Gastrointestinal Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Application
9.3.3.2.4. By Test Location
10. South America Gastrointestinal Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Technology
10.2.3. By Application
10.2.4. By Test Location
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Gastrointestinal Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Application
10.3.1.2.4. By Test Location
10.3.2. Colombia Gastrointestinal Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Application
10.3.2.2.4. By Test Location
10.3.3. Argentina Gastrointestinal Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Application
10.3.3.2.4. By Test Location
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Gastrointestinal Diagnostics Market: SWOT Analysis
